SCHEMBL8983142

SCHEMBL8983142

COc1ccc(COc2ccc(C=O)cc2OCc2ccc(OC)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.65
RAB9A P51151 3/20 0.65
TDP1 Q9NUW8 1/20 0.65
TACR2 P21452 1/20 0.64
PDCD1 Q15116 1/20 0.61
CD274 Q9NZQ7 1/20 0.61
ALDH1A1 P00352 10/20 0.60
MAPT P10636 5/20 0.60
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
FDPS P14324 1/20 0.58
SMN1; SMN2 Q16637 5/20 0.58
CYP2A6 P11509 1/20 0.53
ADAMTS5 Q9UNA0 1/20 0.53
TSHR P16473 1/20 0.53
HTT P42858 2/20 0.52
LMNA P02545 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HPGD P15428 1/20 0.49
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3397230 0.95 PDCD1 (0.67) NPC1RAB9ATDP1TACR2PDCD1
SCHEMBL2699064 0.95 ALDH1A1 (0.66) NPC1RAB9ATDP1TACR2PDCD1
SCHEMBL2463491 0.94 NPC1 (0.63) NPC1RAB9ATDP1TACR2PDCD1
SCHEMBL4241206 0.94 TACR2 (0.74) NPC1RAB9ATDP1TACR2PDCD1
SCHEMBL2556112 0.93 TACR2 (0.76) NPC1RAB9ATDP1TACR2PDCD1
SCHEMBL12335182 0.92 TACR2 (0.60) NPC1RAB9ATDP1TACR2PDCD1
SCHEMBL7784719 0.89 PDCD1 (0.74) NPC1RAB9ATDP1TACR2PDCD1
SCHEMBL22160281 0.88 NPC1 (0.62) NPC1RAB9ATDP1TACR2PDCD1
SCHEMBL24707029 0.88 NPC1 (0.55) NPC1RAB9ATDP1TACR2PDCD1
SCHEMBL988304 0.87 RAB9A (0.60) NPC1RAB9ATDP1TACR2PDCD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024136462-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, IMPROVING OR TREATING ATOPY COMPRISING FLAVONOID DERIVATIVE AS ACTIVE INGREDIENT AND METHOD FOR PREPARING FLAVONOID DERIVATIVE LEEYUN BIO CO.,LTD. (KR) 2024-06-27 WO disclosed
EP-2706062-B1 NOVEL CEPHALOSPORIN DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF LEGOCHEM BIOSCIENCES INC (KR) 2018-05-09 EP disclosed
US-9630977-B2 Cephalosporin derivatives and pharmaceutical compositions thereof LEGOCHEM BIOSCIENCES, INC. (KR) 2017-04-25 US disclosed
EP-2706062-A2 NOVEL CEPHALOSPORIN DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF LegoChem Biosciences, Inc. (KR) 2014-03-12 EP disclosed
EP-2706062-A2 NOVEL CEPHALOSPORIN DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF LegoChem Biosciences, Inc. (KR) 2014-03-12 EP disclosed
US-20130178455-A1 NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF LEGOCHEM BIOSCIENCES, INC (US) 2013-07-11 US disclosed
US-8329684-B2 Cephalosporin derivatives and pharmaceutical compositions thereof LEGOCHEM BIOSCIENCES, INC. (KR) 2012-12-11 US disclosed
US-8329684-B2 Cephalosporin derivatives and pharmaceutical compositions thereof LEGOCHEM BIOSCIENCES, INC. (KR) 2012-12-11 US disclosed
US-20120264727-A1 NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF LEGOCHEM BIOSCIENCES, INC. (KR) 2012-10-18 US disclosed
US-20120264727-A1 NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF LEGOCHEM BIOSCIENCES, INC. (KR) 2012-10-18 US disclosed
WO-2012134184-A2 NOVEL CEPHALOSPORIN DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME 주식회사 레고켐 바이오사이언스 (KR) 2012-10-04 WO disclosed
EP-0409164-B1 Phenacylpyridiniothiocephalosporins SHIONOGI & CO (JP) 1996-06-05 EP disclosed
US-5134138-A ANTIBIOTICS SHIONOGI & CO., LTD. (JP) 1992-07-28 US disclosed
EP-0409164-A2 Phenacylpyridiniothiocephalosporins SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1991-01-23 EP disclosed
US-4568490-A REDUCTIVE CONDENSATION WITH A CARBONYL COMPOUND ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) 1986-02-04 US disclosed
US-4537880-A Aminopropylaminobleomycin derivatives and process for preparation thereof ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) 1985-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178455-A1 NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF CSDE1, CELA1, ABCC1 NPC1 1325/4885RAB9A 2175/4885TDP1 2466/4885
US-20120264727-A1 NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF CSDE1, CELA1, ABCC1 NPC1 1325/4885RAB9A 2175/4885TDP1 2466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.